Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Held

Showing results (91-100 of 108) with videos related to

Pageof 11
Sort By:
Chest|February 6, 2021
Quality of Life 3 and 12 Months Following Acute Pulmonary Embolism: Analysis From a Prospective Multicenter Cohort StudyLuca Valerio, Stefano Barco, Marius Jankowski, et al.
Thrombosis and Haemostasis|December 7, 2017
Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 StudyFrederikus A Klok, Walter Ageno, Stefano Barco, et al.
Circulation|September 17, 2014
Response to letters regarding article, "Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)"Karen M Olsson, Marion Delcroix, H Ardeschir Ghofrani, et al.
European Heart Journal|April 29, 2022
Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS studyLuca Valerio, Anna C Mavromanoli, Stefano Barco, et al.
The European Respiratory Journal|October 22, 2021
Temporal trends in pulmonary arterial hypertension: results from the COMPERA registryMarius M Hoeper, Christine Pausch, Ekkehard Grünig, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|April 17, 2022
Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysisMarius M Hoeper, Christine Pausch, Karen M Olsson, et al.
The European Respiratory Journal|November 5, 2021
COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertensionMarius M Hoeper, Christine Pausch, Karen M Olsson, et al.
European Heart Journal|May 24, 2019
Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trialStefano Barco, Irene Schmidtmann, Walter Ageno, et al.
Rheumatology (Oxford, England)|July 18, 2023
Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysisOliver Distler, Christian Ofner, Dörte Huscher, et al.
The European Respiratory Journal|August 30, 2020
Survival and quality of life after early discharge in low-risk pulmonary embolismStefano Barco, Irene Schmidtmann, Walter Ageno, et al.
Pageof 11

Showing results (91-100 of 108) with videos related to

Sort By:
Pageof 11
Chest|February 6, 2021
Quality of Life 3 and 12 Months Following Acute Pulmonary Embolism: Analysis From a Prospective Multicenter Cohort StudyLuca Valerio, Stefano Barco, Marius Jankowski, et al.
Thrombosis and Haemostasis|December 7, 2017
Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 StudyFrederikus A Klok, Walter Ageno, Stefano Barco, et al.
Circulation|September 17, 2014
Response to letters regarding article, "Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)"Karen M Olsson, Marion Delcroix, H Ardeschir Ghofrani, et al.
European Heart Journal|April 29, 2022
Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS studyLuca Valerio, Anna C Mavromanoli, Stefano Barco, et al.
The European Respiratory Journal|October 22, 2021
Temporal trends in pulmonary arterial hypertension: results from the COMPERA registryMarius M Hoeper, Christine Pausch, Ekkehard Grünig, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|April 17, 2022
Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysisMarius M Hoeper, Christine Pausch, Karen M Olsson, et al.
The European Respiratory Journal|November 5, 2021
COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertensionMarius M Hoeper, Christine Pausch, Karen M Olsson, et al.
European Heart Journal|May 24, 2019
Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trialStefano Barco, Irene Schmidtmann, Walter Ageno, et al.
Rheumatology (Oxford, England)|July 18, 2023
Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysisOliver Distler, Christian Ofner, Dörte Huscher, et al.
The European Respiratory Journal|August 30, 2020
Survival and quality of life after early discharge in low-risk pulmonary embolismStefano Barco, Irene Schmidtmann, Walter Ageno, et al.
Pageof 11